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Abstract
Background
The successful treatment of malignant gliomas remains a challenge despite the current
standard of care, which consists of surgery, radiation and temozolomide. Advances in the
survival of brain cancer patients require the design of new therapeutic approaches that take
advantage of common phenotypes such as the altered metabolism found in cancer cells. It
has therefore been postulated that the high-fat, low-carbohydrate, adequate protein keto-
genic diet (KD) may be useful in the treatment of brain tumors. We have demonstrated that
the KD enhances survival and potentiates standard therapy in a mouse model of malignant
glioma, yet the mechanisms are not fully understood.
Methods
To explore the effects of the KD on various aspects of tumor growth and progression, we
used the immunocompetent, syngeneic GL261-Luc2 mouse model of malignant glioma.
Results
Tumors from animals maintained on KD showed reduced expression of the hypoxia marker
carbonic anhydrase 9, hypoxia inducible factor 1-alpha, and decreased activation of nuclear
factor kappa B. Additionally, tumors from animals maintained on KD had reduced tumor mi-
crovasculature and decreased expression of vascular endothelial growth factor receptor 2,
matrix metalloproteinase-2 and vimentin. Peritumoral edema was significantly reduced in
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animals fed the KD and protein analyses showed altered expression of zona occludens-1
and aquaporin-4.
Conclusions
The KD directly or indirectly alters the expression of several proteins involved in malignant
progression and may be a useful tool for the treatment of gliomas.
Introduction
Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor. Despite surgery,
radiation and chemotherapy, these patients have an average life expectancy of 12–18 months
and less than 10% survive 5 years [1]. Although there have been advances in the development
of novel targeted treatments, these therapies face the challenge of overcoming phenotypic vari-
ability resulting from tumor heterogeneity. One phenotypic trait shared by virtually all cancer
cells is dysregulation of metabolism.
A metabolic shift toward glycolysis regardless of oxygen availability has been observed in
GBM and a variety of other cancers. This phenomenon, first described by Otto Warburg and
called the Warburg Effect [2], supports the synthesis of biomolecules needed to sustain rapid
proliferation, reducing utilization of the tricarboxylic acid cycle and oxidative phosphorylation.
This aberrant metabolism found in tumor cells is now considered a hallmark of cancer [3] and
a potential therapeutic target [4]. One novel approach to targeting tumor metabolism is
through the use of a therapeutic ketogenic diet (KD). The KD is a high-fat, low-carbohydrate
diet that has been implemented in the non-pharmacologic treatment of refractory epilepsy. We
and others have demonstrated that this diet enhances survival in preclinical models of malig-
nant gliomas [5]. We also found that the KD altered the expression of genes involved in the ox-
idative stress response and reduced reactive oxygen species (ROS) in tumors [6]. ROS levels are
often increased in cancer [7] and they play a role in a variety of pathways including tumor an-
giogenesis and growth through the regulation of hypoxia inducible factor-1 (HIF-1) and the
vascular endothelial growth factor (VEGF) pathway [8]. Further, we demonstrated that radia-
tion in combination with KD was synergistic, and survival was significantly increased over ra-
diation treatment alone [9]. While the preclinical work on the KD has led to a limited number
of clinical trials, the mechanisms through which the KD exerts its anti-tumor effects have not
been fully elucidated.
Pathways long known to be associated with tumor cell growth, escape from apoptosis, an-
giogenesis, and therapy resistance have now been linked to cellular metabolism. For example,
hypoxia is a fundamental biological phenomena commonly found in GBM. It drives glycolysis,
energy metabolism and other malignant processes including angiogenesis and invasion [10].
HIF-1 is the key transcriptional regulator of the hypoxic response, upregulating many critical
genes involved with tumor progression. HIF-1 activation facilitates neoangiogenesis and degra-
dation of the extracellular matrix (ECM) by upregulating expression of VEGF, its associated re-
ceptors, and matrix metalloproteinases (MMPs). Further, the malignant hallmarks driven by
hypoxia and HIF-1 expression have been implicated in radio- and chemo-resistance, leading to
poor patient prognosis [11].
The current study explores the KD in the context of tumor hypoxia and angiogenesis. We
show for the first time that the KD given ad libitum significantly reduces the key modulators of
hypoxic response: carbonic anhydrase IX (CA IX) and HIF-1α, and decreases the activation of
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nuclear factor—kappa B (NF-κB). In addition, we found that the KD reduces the expression of
VEGFR2 while decreasing tumor microvasculature and altering the expression of several other
proteins that modify the tumor microenvironment during hypoxia. Our findings suggest that
the KD affects the expression of key proteins involved with the hypoxic response that drives
tumor growth and progression.
Materials and Methods
Ethics statement
This study was performed in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was ap-
proved by the Institutional Animal Care and Use Committee of St. Joseph’s Hospital and Medi-
cal Center (protocol number 334 (A3510-01)). All surgery was performed under ketamine/
xylazine anesthesia, and every effort was made to minimize suffering.
GL261-luc2 mouse model of glioma
Bioluminescent GL261-luc2 cells were derived and grown as previously described [9]. Cells
were harvested and implanted into 10 week old female C57BL/6—cBrd/cBrd/Cr (albino
C57BL/6) mice (National Cancer Institute at Frederick Animal Production Program, Freder-
ick, MD) as described [6,9,12].
Treatment and animal monitoring
Animals were fed standard rodent chow (SD) for 3 days following surgery [12], and were then
randomized to remain on SD ad libitum or changed to KetoCal (KC; Nutricia North America,
Gaithersburg, MD) ad libitum. KC is a nutritionally complete diet providing a 4:1 ratio of fats
to carbohydrates plus protein (72% fat, 15% protein, and 3% carbohydrate). KC paste (2:1 mix
of KC and water) was provided to animals daily. Tumor burden was quantified by biolumines-
cence as described [6]. Serum β-hydroxybutyrate and glucose levels were measured using a Pre-
cision Xtra blood monitoring system (Abbott Laboratories, Abbott Park, IL) and animals were
weighed every 3–4 days.
In vivo imaging of hypoxia
At 21 days post-implantation, HypoxiSense680 (2 nmol/100 μl; PerkinElmer, Inc., Waltham,
MA) was administered by intraperitoneal injection and animals were imaged 24 hours later
using the IVIS Spectrum in vivo imaging system (675 ex/720 em;). Spectral unmixing was per-
formed and quantitation was done using the system’s Living Image 4.3 software. Each tumor
bearing animal was imaged prior to HypoxiSense680 injection to quantitate signal generated
by tissue autofluorescence. Non-tumor bearing mice were injected with HypoxiSense680 and
imaged 24 hours later to quantitate non-specific binding of the probe.
Western blotting
On day 21 post implantation, animals were euthanized, tumor tissue was processed and west-
ern blots were performed as previously described [13]. Protein concentrations were determined
using the Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Primary anti-
bodies included CA IX (1:1000; Proteintech, Chicago, IL), HIF-1α (1:500; Bioss, Woburn,
MA), NF-κB (1:1000; Cell Signaling Technology), phosphorylated NF-κB (p-NF-κB; 1:1000;
Cell Signaling Technology), CD31 (1:5000; Novus Biologicals, Littleton, CO), VEGF (1:1000;
Santa Cruz Biotechnology, Dallas, TX), VEGF receptor 2 (VEGFR2; 1:5000; Novus
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Biologicals), MMP-2 (1:500; Bioss), MMP-9 (1:600; Novus Biologicals), Vimentin (1:200, Santa
Cruz Biotechnology), zona occudins-1 (ZO-1; 1:200; Biorbyt, Cambridge, UK), Occludin (1:40;
Biorbyt), Aquaporin-1 (1:1000; Abcam, Cambridge, UK) and Aquaporin-4 (1:1000; Abcam),
and β-actin (1:6000; Abcam). Densitometry was used to determine the ratio of the target to β-
actin (VisionWorks LS 7.1 software; UVP, Upland, CA).
Immunohistochemistry
Formalin fixed paraffin-embedded tissue sections were deparaffinized followed by antigen re-
trieval in sodium citrate buffer (10 mM; pH 6.0) at 98°C for 25 min. Sections were blocked with
1% bovine serum albumin in TBST for 1 hour at room temperature (RT) and incubated in
Image-iT FX signal enhancer (Life Technologies, Carlsbad, CA) for 30 minutes at RT. Sections
were incubated with anti-CD31 antibody (1:2500, Novus Biologicals) overnight at 4°C followed
by AlexaFluor 488 goat anti-rabbit IgG antibody (1:1500, Life Technologies) for 1 hour at RT.
Lipofucsin induced autofluorescence was reduced using 1 mM CuSO4 diluted in 50 nM ammo-
nium acetate buffer (pH 5) as previously described [14]. Sections were counterstained with
VectaShield mounting media containing DAPI (Vector Laboratories, Burlingame, CA) and im-
aged using a Zeiss LSM 710 microscope (Carl Zeiss International, Gottingen, Germany) and
Zen software (Zeiss). Total CD31 staining was determined by averaging the pixel density in 5
random, 200x fields within the same tumor for each animal using Image J software (NIH, Be-
thesda, MD). The percentage of CD31 positive staining per analyzed area of the tumor was de-
termined by normalized pixel threshold analysis.
Gene expression analysis
Total cellular RNA from tumor tissue was isolated using TRIzol LS Reagent (Life Technologies)
and conditions specified by the manufacturer. RNA was further purified using an RNeasy Mini
Kit (Qiagen, Valencia, CA), DNased using TURBO DNase (Ambion, Life Technologies) and
the quality was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). The Mouse Cancer RT2 Profiler PCR Array was performed as a fee-for-service by
Qiagen.
Measurement of peritumoral edema
On Day 14 following tumor implantation, MR images were acquired on a Bruker Biospec 7.0T
small animal MR scanner (Bruker Medizintechnik, Karlsruhe, Germany) with 72mm transmit
coil and a surface receive coil. A multiple slice 2D T2-weighted RARE sequence was acquired
as reference image (29 slices, 0.1 mm x 0.1 mm, thickness 0.5 mm, TR = 4000 ms, effective
TE = 60 ms, RARE factor = 8) to locate the slice with maximum tumor size. A multi-echo T2
relaxometry sequence was used for T2 mapping, in which a series of T2-weighted images were
obtained at 28 different echo times, starting from 10.57ms with 10.57ms increments, with in-
plane resolution of 0.078 mm x 0.078 mm, slice thickness 1.0 mm, matrix size = 192 x 192,
field of view = 15 mm x15 mm, repetition time = 3000 ms. The T2 map was derived by single-
exponential fitting of the data.
Statistical methods
Statistical analyses were performed using GraphPad Prism v 5.04 (GraphPad Software, San
Diego, CA). All values are represented as the mean ± SD and significance was determined
using the Student’s t test. P< 0.05 was considered statistically significant.
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Results
Animals fed KC show increased β-hydroxybutyrate levels and a
reduction in blood glucose
Animals fed KC had a statistically significant increase in blood βHB levels (Fig 1A) and de-
creased blood glucose (Fig 1B) both 7 and 14 days post-implantation. Body weight remained
relatively stable throughout the course of the experiment (Fig 1C). Body weights demonstrated
a slight decline throughout the experiment as the tumor grows and animals start becoming
symptomatic, consistent with our previous results [9]. At day 14 post-implantation there was a
slight decrease in average body weight for the animals fed KC however this was not significant.
On day 21 post-implantation, animals were euthanized to obtain tissue for ex vivo analyses.
KC reduces in vivo expression of carbonic anhydrase IX
To determine the effect of the KC on hypoxia, the fluorescent imaging agent HypoxiSense 680
was used to detect in vivo expression of the hypoxia marker carbonic anhydrase IX (CA IX) on
the surface of tumor cells. Animals maintained on KC had a statistically significant reduction
Fig 1. Weight, βHB and glucosemeasurements. Blood ketone and glucose measurements show (A) higher βHB and (B) lower glucose in KC treated
animals (C) weight measurements were taken every 3 days. Graph shows weights normalized to the average starting weight of each group. (N = 5; *p < 0.05;
**p < 0.01; ***p < 0.001).
doi:10.1371/journal.pone.0130357.g001
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in HypoxiSense 680 signal when compared to animals fed SD (Fig 2A and 2B). Tumor bearing
animals were imaged prior to injection of the probe to quantitate signal generated by tissue
autofluorescence (Fig 2B). Non-tumor bearing mice were injected with the probe and imaged
24 hours later to quantitate non-specific binding of the probe (Fig 2B). To confirm that this ef-
fect was not a result of tumor size, bioluminescence was measured and showed no significant
difference between treatment groups (Fig 2C).
KC reduces expression of proteins involved with the hypoxic response
Western blot analysis of tumor lysates was performed to study the effects of KC on the expres-
sion of proteins important in the hypoxic response. Both CA IX and HIF-1α levels were signifi-
cantly reduced in the tumors from animals fed KC when compared to those fed SD (Fig 3;
N = 6; p< 0.05; p< 0.01). Further, although there was no difference in total NF-κB expres-
sion, there was a significant reduction in the phosphorylated form, suggesting a reduction in
the activation of NF-κB (Fig 3).
KC reduces tumor microvasculature
To assess the effect of KC on tumor microvasculature and the expression of the angiogenic
marker CD31, we performed immunohistochemical staining of paraffin-embedded tissue sec-
tions (Fig 4A). Quantitation of staining demonstrated a statistically significant decrease in the
percentage of CD31 positive areas within the tumors of animals fed KC (Fig 4B). These results
were confirmed with western blot analysis of CD31 from whole lysate of GL261-luc2 tumors
(Fig 5A) which demonstrated a statistically significant 2-fold decrease in expression of CD31 in
animals fed KC when compared to SD fed animals (Fig 5B).
KC alters expression of genes involved in angiogenesis and vascular
modeling
The expression of key regulators of tumor angiogenesis, VEGF and VEGFR2, was analyzed by
western blot. There was no difference in total VEGF expression; however, a significant reduc-
tion in VEGFR2 expression was found (Figs 5A and 4B).
Tumor RNA was analyzed from animals fed KC and animals fed SD using a mouse Cancer
RT2 Profiler PCR Array (Qiagen). The expression of a number of genes involved in various
angiogenenic processes were found to be altered by KC (Fig 5C). Of those genes, Vegfb, Plau,
Timp1, Tek, and Itgb1 were expressed significantly lower in the tumors from animals fed a KC
when compared to tumors from animals fed SD.
KC alters the expression of genes involved in invasive potential
We analyzed tumor invasive potential by performing western blot analysis on tumor tissue to
determine the expression levels of vimentin, MMP-9 and both the pro-form and the proteolyti-
cally processed activated form of MMP-2. Tumors from animals maintained on KC showed a
significant reduction in both the pro- (72 KDa) and activated (65 KDa) form of MMP-2 as well
as a reduction in expression of vimentin (Fig 6A and 6B). Although there was a slight reduction
in expression of MMP-9 in the tumors from animals maintained on KC, the difference was not
statistically significant.
KC reduces peritumoral edema
The reduction in angiogenesis suggested that animals maintained on KC may have a reduction
in peritumoral edema. MRI analysis on day 14 following implantation was done to measure
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Fig 2. In vivo imaging of hypoxia. (A) The fluorescent probe HypoxiSense 680 was used to analyze
hypoxia in vivo 21 days following tumor implantation. (B) Fluorescent signal was quantitated from tumor
bearing mice (N = 5; *p < 0.05). Animals were imaged prior to injection to analyze tissue autofluorescence
(“Before injection”; N = 5; ***p < 0.001). Non-tumor bearing mice were injected to analyze non-specific
binding (“Normal Brain”; N = 2; *p < 0.05). (C) Tumor bioluminescence imaging showed no significant
difference between SD and KC (N = 5).
doi:10.1371/journal.pone.0130357.g002
The Ketogenic Diet Alters Multiple Pathways in Glioma
PLOSONE | DOI:10.1371/journal.pone.0130357 June 17, 2015 7 / 18
Fig 3. Western blot analysis of CA IX, HIF-1α, phospho-NF-κB, and total NF-κB. (A) Western blots
showing two representative samples per treatment group. (B) On day 21 post-implantation expression was
quantified and represented as a fold change from SD (N = 6; *p < 0.05; **p < 0.01).
doi:10.1371/journal.pone.0130357.g003
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edema (Fig 7A), which is reflected by an increase in T2. Results show a statistically significant
2-fold decrease in peritumoral edema in animals fed KC when compared to those fed SD
(Fig 7B). To demonstrate that the reduction in edema with the KC was not purely a function
tumor size, bioluminescent tumor signals from the same day were analyzed and there was no
statistical difference in signal between groups (Fig 7C).
KC influences expression of tight junction proteins and aquaporins
Western blot analysis of tumor tissue was performed to analyze the expression of proteins in-
volved with peritumoral edema and glioma progression including the tight junction proteins,
ZO-1 and occludin, as well as the water channeling proteins, AQPN-1, AQPN-4. Tumors from
animals fed KC had a significant increase in the expression of ZO-1 but no difference in occlu-
din expression (Fig 8A and 8B). Animals maintained on KC also showed a reduction in expres-
sion of AQPN-4 expression but not AQPN-1 (Fig 8A and 8C).
Discussion
Hypoxia is a fundamental biological phenomena found in a variety of solid tumors. HIF-1 ac-
tivity is regulated by rapid stabilization of the HIF1α subunit and acts as a crucial transcrip-
tional factor in the cellular response to hypoxia [15]. HIF-1 can facilitate angiogenesis and
invasion through upregulation of various target genes including VEGF, VEGF receptors and
MMPs [15]. CA IX expression is also controlled by HIF-1α and is thus considered a marker for
hypoxia. Overexpression of CA IX is common in malignant glioma and correlates with poor
patient survival [16]. The current study found a reduction in the expression of HIF-1α and CA
IX in tumors from animals maintained on the KD, suggesting reduced hypoxia in these tumors.
We propose that the resulting alterations in angiogenesis, specifically involving the VEGF
pathway, may be a factor in the anti-tumor effect seen with the KD. Preclinical and clinical
studies have demonstrated that tumor growth and progression can be limited by targeting an-
giogenesis [17].
Fig 4. Analysis of tumor microvasculature components and gene expression. (A) CD31 immunostaining of tissue harvested at 21 days post-
implantation. Representative images are shown. (B) Quantification of CD31 staining was performed on 2 independent tumors from each group. Data
calculated as the average pixel density in 5 random, 200x fields within the same tumor and represented as a fold change from SD (**p < 0.01).
doi:10.1371/journal.pone.0130357.g004
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In this study we demonstrated that the KD significantly reduced protein expression of
VEGFR2, the main receptor responsible for modulating tumor angiogenesis [18]. Recent stud-
ies have shown that selective inhibition of VEGFR2 tyrosine kinase induces a radiologic re-
sponse, normalizes tumor vasculature, and reduces edema while increasing patient quality of
life [17]. Further, it has been suggested that a VEGFR2 blockade creates a "normalization win-
dow" where vessel structure is normalized and hypoxia is reduced, enhancing radiation therapy
in human glioblastoma xenograft models [19]. In our studies, total VEGF at the protein level
was not significantly altered by the KD however RNA analysis showed a significant decrease in
the expression of Vegfb. Although the role of VEGFB in tumor angiogenesis is not well under-
stood, it may be important for angiogenic processes in a context dependent manner [20]. De-
creased VEGFB expression is associated with improved survival and may be an indicator of
response to anti-angiogenic therapies in ovarian cancer patients [21]. Bevacizumab, the only
FDA-approved anti-angiogenesis drug for use in GBM, is a humanized monoclonal antibody
Fig 5. Western blot analysis of CD31, VEGF and VEGFR2. (A) Western blots showing two representative samples per treatment group. (B) At day 21 post
implantation expression was quantified and represented as a fold change from SD (N = 6 for SD and N = 5 for KC; *p < 0.05). (C) Expression of genes
involved in angiogenesis was analyzed using RT-PCR. Data represented as the fold change difference in expression from SD tumors (N = 3; *p < 0.05;
**p < 0.01).
doi:10.1371/journal.pone.0130357.g005
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that targets VEGFA [22]. While it is has been used for recurrent tumor, it often results in ad-
verse side effects and there is considerable controversy as to its efficacy [23]. Bevacizumab can
lead to increased regions of hypoxia, a more invasive, treatment-resistant glioma phenotype
and enhanced MMP-2 activation [24]. MMPs remodel the extracellular matrix and alter sur-
face protein expression. Increased expression and activation of MMP-2, which is linked to
HIF-1α expression, can lead to cellular invasion and increased blood-brain barrier (BBB) per-
meability [25]. Silencing pro-MMP-2 resulted in decreased expression of VEGFR2 and en-
hanced radiosensitivity in a human xenograft model [26]. Protein analysis of tumors from
animals fed the KD showed reduced expression of both pro- and activated-MMP-2, and the
mesenchymal marker, vimentin, which is upregulated in the epithelial-to-mesenchymal transi-
tion (EMT) that occurs within invasive glioma cells [27,28]. Together these results suggest that
a KD may reduce the invasive potential of cells within the tumor. If metabolic therapy could be
used to mimic the beneficial effects of bevacizumab it may provide a less toxic way to limit an-
giogenesis while limiting pro-invasive selection.
An additional reason angiogenesis presents a clinical challenge is that in contrast to healthy
vessels, tumor vasculature is often immature, highly permeable, structurally and functionally
abnormal [29]. This can impair delivery of therapeutic agents, alter the tumor microenviron-
ment, drive tumor cell extravasation and allow for the rapid influx of inflammatory cells [30].
Inflammation can lead to peritumoral edema, which is a frequent cause of morbidity and mor-
tality in patients with gliomas. Dexamethasone is the current treatment of choice for peritu-
moral inflammation and edema, yet it comes with adverse side effects such as hyperglycemia,
cardiovascular effects, osteoporosis, weight gain, insomnia, increased susceptibility to infection
and cognitive effects which ultimately reduce the quality of life for patients [31]. Hyperglyce-
mia induced by corticosteroids has been linked to shorter survival and may have a negative im-
pact on adjuvant chemoradiotherapy in GBM patients [32–34].
Fig 6. Western blot analysis of pro- and activated- MMP-2, MMP-9, and vimentin. (A) Western blots showing two representative samples per treatment
group. (B) On day 21 post-implantation expression was quantified and represented as a fold change from SD (N = 6 for SD; N = 5 for KC; *p < 0.05).
doi:10.1371/journal.pone.0130357.g006
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The current study found a reduction in glucose and peritumoral edema in animals main-
tained on the KD when compared to those fed SD. Animals maintained on the KD also showed
a significant reduction in activation of NF-κB in their tumors, which is another key regulator
of the transcriptional response to hypoxia [35]. NF-κB is linked to various signal transduction
pathways and to transcriptional activation events that mediate inflammation, cell proliferation,
cell migration, and angiogenesis [36].
Leaky vasculature and disruption of the blood brain barrier caused by tumors is thought to
occur in part because of defects in interendothelial tight junctions. ZO-1 and occludin are criti-
cal for maintaining the stability and functions of the tight junctions, and their loss is associated
with increased blood brain barrier permeability [37]. ZO-1 expression was significantly in-
creased in the tumors from animals fed the KD when compared to SD; however, there was no
difference in expression of occludin. Further, both irradiation and hypoxic conditions have
been implicated in the breakdown of the BBB via down-regulation of ZO-1 expression in
Fig 7. Peritumoral edemameasurements. (A) Representative MRI image of tumor bearing mouse (B) 14 days following tumor implantation, edema was
measured via MRI. A 2-fold decrease in peritumoral edema was seen in animals fed KC compared to SD (N = 3; *p < 0.05). (C) Tumor bioluminescence
imaging showed no significant difference in tumor size between treatments.
doi:10.1371/journal.pone.0130357.g007
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gliomas [38]. Our results suggest that the KD may help mitigate peritumoral edema and BBB-
breakdown by preserving ZO-1 expression.
Brain edema and BBB permeability are also propagated by HIF-1α expression which can in-
crease expression of MMPs and aquaporin-4 (AQP4) [39]. Several groups have proposed the
involvement of aquaporins in the pathophysiology of brain edema [40]. Aquaporins are the
principle pathway for water movement across most cellular membranes. Of these, AQP1 and
AQP4 proteins are found highly expressed in the most malignant gliomas [41]. The current
Fig 8. Western blot analysis of ZO-1, occludin, aquaporin-1 and Aquaporin-4. (A) Western blots showing two representative samples per treatment
group. (B,C) On day 21 post-implantation expression was quantified and represented as a fold change from SD (N = 6 for SD; N = 5 for KC; *p < 0.05;
**p < 0.01).
doi:10.1371/journal.pone.0130357.g008
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study found a reduction in expression of AQP4 but not AQP1 in the tumors from animals fed
a KD. In addition to its well-known function in brain edema, AQP4 has also been recently re-
ported to play a role in cell migration, invasion and survival [40]. Further analysis of gene ex-
pression showed tumors in mice fed KC also had significantly lower expression of plasminogen
activator urokinase (Plau) and angiopoeitin-1 receptor (Tek). Both are thought to play a central
role in tumor invasion, metastasis and angiogenesis [42]. PLAU inhibitors are being actively
explored as anticancer strategies in glioblastomas and may have antiangiogenic properties
[43,44]. TEK was also shown to be a key molecular regulator of pathological vascularization in
a number of preclinical brain tumor models [45–47]. We found that beta 1 integrin (Itgb1) and
tissue inhibitor of metalloproteinase 1 (Timp1) expression was significantly reduced when ani-
mals were maintained on KC. Beta1 integrin has been implicated in tumorigenesis, therapy re-
sistance, invasion and metastasis [48]. Inhibitors of Itgb1are being explored as a treatment for
various cancers and have been shown to potentiate antiangiogenic therapy in bevacizumab re-
sistant glioblastoma [49]. In addition, low expression levels of TIMP-1 have been associated
with longer survival times in GBM patients [50]. Recently TIMP-1 upregulation has also been
shown to be involved in mechanisms of developed resistance to anti-VEGF treatment [51].
These results taken together suggest a potential utility of the KD as an adjuvant treatment for
brain tumors and highlight the importance of metabolism in tumor progression.
The use of metabolism as a therapeutic target is not new. In 1914, Payton Rous first sug-
gested that restricted food intake reduced tumor growth by reducing the tumor blood supply
[52], and early attempts to use metabolism as a therapeutic target often focused on caloric re-
striction (CR). The combination of CR and the KD (restricted ketogenic diet; RKD) is also
being explored as a cancer therapy. Both mouse and human xenograft models have been used
to substantiate the anti-proliferative and anti-angiogenic effects of CR and the RKD [53]. Evi-
dence also suggests that CR and the RKD have similar anti-tumor mechanisms to the unre-
stricted KD Including the alteration of pathways involving with inflammation, normalization
of vasculature and peritumoral edema. In a mouse astrocytoma model, CR reduced expression
of pro-inflammatory markers, cyclooxygenase-2, NF-κB and macrophage inflammatory pro-
tein [13]. Seyfried and colleagues recently used the CT-2A mouse astrocytoma model to show
that CR caused a reduction in VEGF expression and promoted vessel maturation, presumably
by preventing the association of VEGFR2 and platelet-derived growth factor receptor β [54].
Further, a recent study using CR in a U87 human glioma xenograft model showed a reduction
of peritumoral edema and normalization of a variety of factors involved in tumor vessel insta-
bility and leakiness, including VEGF expression [55]. While CR and RKD can easily be admin-
istered in animal models of malignant tumors and there is anecdotal evidence and a few case
reports of efficacy in humans, there has been resistance in the medical community to use CR
for cancer patients. An alternative strategy is the KD without caloric restriction as used for the
treatment of refractory pediatric epilepsy. This approach may meet less resistance in the clinic,
as it has a long safety record and may be easier for patients to maintain [56]. Interestingly,
Zhou and colleagues found a trend toward increased survival when administering an unre-
stricted KD (UKD) in a CT2A mouse astrocytoma model [57], however the results weren’t sta-
tistically significant. The authors observed no change in glucose and relatively low βHB levels
with the UKD when compared to the data presented above, which may explain the discrepan-
cy. Zhou’s data and the current study highlight the importance of identifying an optimal thera-
peutic window for βHB and glucose as well as determining which tumor types and subtypes
are likely to respond better to the KD.
The mechanisms underlying the anti-tumor benefits of the ketogenic diet, caloric restriction
(and intermittent fasting) and other potential metabolic therapies have not yet been fully eluci-
dated; however, preclinical data strongly suggests that metabolic alteration may be a highly
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effective therapy and may in fact enhance the current standard of care for malignant gliomas.
The KD and/or CR are the only therapeutic approaches that simultaneously target multiple
hallmarks of cancer such as energy metabolism, inflammation, hypoxia, angiogenesis and inva-
sion. It is not clear whether the KD directly causes all of these changes in the tumor, or if some
may be a result of changes in the tumor and/or tumor microenvironment that results from the
KD. Indeed, a number of the effects seen such as reduction in peritumoral edema, alterations
in hypoxia, etc are known to affect a number of downstream targets. Whether the specific
changes are directly or indirectly due to the KD, it is clear that the overall result has powerful
anti-tumor effects in our preclinical model of glioma. This not only highlights the interconnec-
tedness of metabolism with other aspects of tumor growth and progression, but suggests a po-
tential utility for the KD in the treatment of malignant brain tumors.
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